BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research
On March 13, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation. In multiple comparisons of preservation efficacy of patient-derived xenograft (PDX) tumors, […]
BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results
BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results Revenue Increased 39% for the Quarter and 34% for the Year Achieves Positive Cash Flow from Operations for the Year Reaffirms Guidance for 2018 Operating Profit On March 8, 2018 BioLife Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue […]
BioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018
BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media (“BioLife” or the “Company”), announced that the Company’s fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018, and that the Company will host a […]
BioLife Solutions Executes OEM Agreement with MilliporeSigma
BioLife Solutions Executes OEM Agreement with MilliporeSigma Private Labeled CryoStor® Cell Freeze Media and HypoThermosol® Cell and Tissue Storage and Shipping Media Distributed to Worldwide Biotech Research Market On February 13, 2018 BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has […]
Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study
Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno- modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during biopreservation/stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe. […]
BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million
Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016 On January 4, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018. […]
BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics
On December 13, 2017 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (“Iovance”) (NASDAQ: IOVA). Iovance is […]
Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea
Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions […]
BioLife Solutions to Present at September Investment Conferences
BioLife Solutions Inc. (NASDAQ: BLFS) announces that Mike Rice, President and CEO, will be presenting at two investment conferences in September: Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12th, at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the New York Palace Hotel in New York […]
BioLife Solutions Executes Supply Agreement with Celyad
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies BioLife is pleased to announce that it has executed a long term supply agreement with NASDAQ-listed Celyad, […]